MLF1/MLF2 Polyklonale Antilichaam, FITC-vervoeging

Involved in lineage commitment of primary hemopoietic progenitors by restricting erythroid formation and enhancing myeloid formation. Interferes with erythropoietin-induced erythroid terminal differentiation by preventing cells from exiting the cell cycle through suppression of CDKN1B/p27Kip1 levels. Suppresses RFWD2/COP1 activity via CSN3 which activates p53 and induces cell cycle arrest. Binds DNA and affects the expression of a number of genes so may function as a transcription factor in the nucleus.

Hls7; MLF1; MLF2; MLF3; MLF1_HUMAN; Myelodysplasia myeloid leukemia factor 1; Myelodysplasia-myeloid leukemia factor 1; Myeloid leukemia factor 1; myeloid leukemia factor 1 variant 1; myeloid leukemia factor 1 variant 2; myeloid leukemia factor 1 variant 3.

4291

Human, Mouse, Rat

165-268/268

MLF1/MLF2

FITC

KLH conjugated synthetic peptide derived from human MLF1/2/3

WB, IF (IHC-P)

Purified by Protein A.

494nm/518nm

1µg/µl

WB (1:300-5000), IF (IHC-P) (1:50-200)

Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Unmodified

Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

4291

Cow, Sheep, Pig